315 related articles for article (PubMed ID: 37434262)
1. Spatially resolved transcriptomic profiles reveal unique defining molecular features of infiltrative 5ALA-metabolizing cells associated with glioblastoma recurrence.
Andrieux G; Das T; Griffin M; Straehle J; Paine SML; Beck J; Boerries M; Heiland DH; Smith SJ; Rahman R; Chakraborty S
Genome Med; 2023 Jul; 15(1):48. PubMed ID: 37434262
[TBL] [Abstract][Full Text] [Related]
2. The Invasive Region of Glioblastoma Defined by 5ALA Guided Surgery Has an Altered Cancer Stem Cell Marker Profile Compared to Central Tumour.
Smith SJ; Diksin M; Chhaya S; Sairam S; Estevez-Cebrero MA; Rahman R
Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29156557
[TBL] [Abstract][Full Text] [Related]
3. A longer time to relapse is associated with a larger increase in differences between paired primary and recurrent IDH wild-type glioblastomas at both the transcriptomic and genomic levels.
Ho WM; Chen CY; Chiang TW; Chuang TJ
Acta Neuropathol Commun; 2024 May; 12(1):77. PubMed ID: 38762464
[TBL] [Abstract][Full Text] [Related]
4. MRI-localized biopsies reveal subtype-specific differences in molecular and cellular composition at the margins of glioblastoma.
Gill BJ; Pisapia DJ; Malone HR; Goldstein H; Lei L; Sonabend A; Yun J; Samanamud J; Sims JS; Banu M; Dovas A; Teich AF; Sheth SA; McKhann GM; Sisti MB; Bruce JN; Sims PA; Canoll P
Proc Natl Acad Sci U S A; 2014 Aug; 111(34):12550-5. PubMed ID: 25114226
[TBL] [Abstract][Full Text] [Related]
5. Systematic histopathological analysis of different 5-aminolevulinic acid-induced fluorescence levels in newly diagnosed glioblastomas.
Kiesel B; Mischkulnig M; Woehrer A; Martinez-Moreno M; Millesi M; Mallouhi A; Czech T; Preusser M; Hainfellner JA; Wolfsberger S; Knosp E; Widhalm G
J Neurosurg; 2018 Aug; 129(2):341-353. PubMed ID: 29076783
[TBL] [Abstract][Full Text] [Related]
6. Metabolic-related gene pairs signature analysis identifies ABCA1 expression levels on tumor-associated macrophages as a prognostic biomarker in primary IDH
Wang S; Li L; Zuo S; Kong L; Wei J; Dong J
Front Immunol; 2022; 13():869061. PubMed ID: 36248907
[TBL] [Abstract][Full Text] [Related]
7. Integration analysis of single-cell and spatial transcriptomics reveal the cellular heterogeneity landscape in glioblastoma and establish a polygenic risk model.
Liu Y; Wu Z; Feng Y; Gao J; Wang B; Lian C; Diao B
Front Oncol; 2023; 13():1109037. PubMed ID: 37397378
[TBL] [Abstract][Full Text] [Related]
8. Molecular Evolution of
Draaisma K; Chatzipli A; Taphoorn M; Kerkhof M; Weyerbrock A; Sanson M; Hoeben A; Lukacova S; Lombardi G; Leenstra S; Hanse M; Fleischeuer R; Watts C; McAbee J; Angelopoulos N; Gorlia T; Golfinopoulos V; Kros JM; Verhaak RGW; Bours V; van den Bent MJ; McDermott U; Robe PA; French PJ
J Clin Oncol; 2020 Jan; 38(1):81-99. PubMed ID: 31743054
[TBL] [Abstract][Full Text] [Related]
9. A comparative study of primary and recurrent human glioblastoma multiforme using the small animal imaging and molecular expressive profiles.
Lin LT; Chiou SH; Lee TW; Liu RS; Hwang JJ; Chang CH; Ma HI; Lee YJ
Mol Imaging Biol; 2013 Jun; 15(3):262-72. PubMed ID: 22948536
[TBL] [Abstract][Full Text] [Related]
10. Integrative analysis of transcriptome and proteome profiles in primary and recurrent glioblastoma.
Zhang J; Wang G; Yan B; Yang G; Yang Q; Hu Y; Guo J; Zhao N; Wang L; Wang H
Proteomics Clin Appl; 2024 May; 18(3):e2200085. PubMed ID: 38037768
[TBL] [Abstract][Full Text] [Related]
11. Nuclear respiratory factor 1 transcriptomic signatures as prognostic indicators of recurring aggressive mesenchymal glioblastoma and resistance to therapy in White American females.
Bhawe K; Das JK; Yoo C; Felty Q; Gong Z; Deoraj A; Liuzzi JP; Ehtesham NZ; Hasnain SE; Singh VP; Mohapatra I; Komotar RJ; Roy D
J Cancer Res Clin Oncol; 2022 Jul; 148(7):1641-1682. PubMed ID: 35441887
[TBL] [Abstract][Full Text] [Related]
12. 5-Aminolevulinic Acid Guided Sampling of Glioblastoma Microenvironments Identifies Pro-Survival Signaling at Infiltrative Margins.
Ross JL; Cooper LAD; Kong J; Gutman D; Williams M; Tucker-Burden C; McCrary MR; Bouras A; Kaluzova M; Dunn WD; Duong D; Hadjipanayis CG; Brat DJ
Sci Rep; 2017 Nov; 7(1):15593. PubMed ID: 29142297
[TBL] [Abstract][Full Text] [Related]
13. Spatial immunosampling of MRI-defined glioblastoma regions reveals immunologic fingerprint of non-contrast enhancing, infiltrative tumor margins.
Grabowski MM; Watson DC; Chung K; Lee J; Bayik D; Lauko A; Alban T; Melenhorst JJ; Chan T; Lathia JD; Ahluwalia MS; Mohammadi AM
medRxiv; 2023 Mar; ():. PubMed ID: 36945620
[TBL] [Abstract][Full Text] [Related]
14. "Zooming in" on Glioblastoma: Understanding Tumor Heterogeneity and its Clinical Implications in the Era of Single-Cell Ribonucleic Acid Sequencing.
Khalafallah AM; Huq S; Jimenez AE; Serra R; Bettegowda C; Mukherjee D
Neurosurgery; 2021 Feb; 88(3):477-486. PubMed ID: 32674143
[TBL] [Abstract][Full Text] [Related]
15. GBMdeconvoluteR accurately infers proportions of neoplastic and immune cell populations from bulk glioblastoma transcriptomics data.
Ajaib S; Lodha D; Pollock S; Hemmings G; Finetti MA; Gusnanto A; Chakrabarty A; Ismail A; Wilson E; Varn FS; Hunter B; Filby A; Brockman AA; McDonald D; Verhaak RGW; Ihrie RA; Stead LF
Neuro Oncol; 2023 Jul; 25(7):1236-1248. PubMed ID: 36689332
[TBL] [Abstract][Full Text] [Related]
16. Differential gene expression in peritumoral brain zone of glioblastoma: role of SERPINA3 in promoting invasion, stemness and radioresistance of glioma cells and association with poor patient prognosis and recurrence.
Nimbalkar VP; Kruthika BS; Sravya P; Rao S; Sugur HS; Verma BK; Chickabasaviah YT; Arivazhagan A; Kondaiah P; Santosh V
J Neurooncol; 2021 Mar; 152(1):55-65. PubMed ID: 33389566
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenomic profiling reveals molecular features of chemotherapy resistance in IDH wild-type primary glioblastoma.
Nam Y; Koo H; Yang Y; Shin S; Zhu Z; Kim D; Cho HJ; Mu Q; Choi SW; Sa JK; Seo YJ; Kim Y; Lee K; Oh JW; Kwon YJ; Park WY; Kong DS; Seol HJ; Lee JI; Park CK; Lee HW; Yoon Y; Wang J
Genome Med; 2023 Mar; 15(1):16. PubMed ID: 36915208
[TBL] [Abstract][Full Text] [Related]
18. Identification of a unique tumor cell subset employing myeloid transcriptional circuits to create an immunomodulatory microenvironment in glioblastoma.
Yang K; Shi Y; Luo M; Mao M; Zhang X; Chen C; Liu Y; He Z; Liu Q; Wang W; Luo C; Yin W; Wang C; Niu Q; Zeng H; Bian XW; Ping YF
Oncoimmunology; 2022; 11(1):2030020. PubMed ID: 35096487
[TBL] [Abstract][Full Text] [Related]
19. New insights for precision treatment of glioblastoma from analysis of single-cell lncRNA expression.
Meng Q; Zhang Y; Li G; Li Y; Xie H; Chen X
J Cancer Res Clin Oncol; 2021 Jul; 147(7):1881-1895. PubMed ID: 33693962
[TBL] [Abstract][Full Text] [Related]
20. Combining single-cell sequencing and spatial transcriptome sequencing to identify exosome-related features of glioblastoma and constructing a prognostic model to identify BARD1 as a potential therapeutic target for GBM patients.
Zhao S; Wang Q; Ni K; Zhang P; Liu Y; Xie J; Ji W; Cheng C; Zhou Q
Front Immunol; 2023; 14():1263329. PubMed ID: 37727789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
